Feb 22, 2026 by Daniel SparksIs CrowdStrike Stock a Buy After Falling 17% Year to Date?CrowdStrike is still growing quickly, but the stock's valuation assumes that pace holds up with little noise.
Feb 22, 2026 by James BrumleyMy 5 Favorite Dividend Stocks to Buy Right NowThere are several solid prospects to choose from right now, but there's a reason I can't get these particular names out of my head.
Feb 22, 2026 by Reuben Gregg BrewerLeveraged ETFs Are Among the Market's Most Aggressive Investment Tools. But Should You Avoid Them Altogether?What if you could double or even triple the market's return? Is it worth the risk?
Feb 22, 2026 by Daniel SparksIs CrowdStrike Stock a Buy After Falling 17% Year to Date?CrowdStrike is still growing quickly, but the stock's valuation assumes that pace holds up with little noise.
Feb 22, 2026 by Todd ShriberBetting Against Wall Street: The Inverse ETF Surge No One Is Talking AboutThe ProShares UltraShort Financials ETF ratchets up bearish bets on a popular sector.
Feb 22, 2026 by Micah Zimmerman2 Quantum Computing Stocks That Could Make a MillionaireQuantum computing is still a high-risk frontier, but for patient investors, these two tickers could be tomorrow's generational wealth creators.
Feb 22, 2026 by Jonathan PoncianoPraxis Stock Surges 320% as One Biotech Investor's Buy Pushes Stake to Nearly $600 MillionPraxis Precision Medicines targets neurological and psychiatric disorders with a pipeline of precision therapies for CNS conditions.
Feb 22, 2026 by Jonathan PoncianoCelcuity Stock Soars 700% in a Year as One Investor's $17 Million Buy Helps Create Top Two PositionCelcuity develops targeted cancer therapies and diagnostic platforms, with a focus on advancing precision medicine in oncology.
Feb 22, 2026 by Dave Kovaleski2 Financial Stocks Poised for a Comeback in 2026Both stocks are in the Berkshire Hathaway portfolio, selected by former CEO Warren Buffett.
Feb 22, 2026 by Jonathan PoncianoApogee Shares Up Nearly 100% in 12 Months, and This $62 Million Buy Signals Ongoing ConvictionApogee Therapeutics develops biologic therapies targeting dermatology and respiratory conditions, with lead candidates in clinical trials.
Feb 22, 2026 by James BrumleyMy 5 Favorite Dividend Stocks to Buy Right NowThere are several solid prospects to choose from right now, but there's a reason I can't get these particular names out of my head.
Feb 22, 2026 by Stefon WaltersAre You Really Ready to Start Collecting Social Security? 3 Signs It Might Be the Perfect TimeChecking these boxes can help ease your claiming decision.
Feb 22, 2026 by Jonathan Ponciano$80 Million Arcellx Sale Follows Steep Stock Drop as Rival Drug EmergesArcellx develops next-generation cell therapies targeting multiple myeloma and other hematologic cancers in the biotechnology sector.
Feb 22, 2026 by Reuben Gregg BrewerLeveraged ETFs Are Among the Market's Most Aggressive Investment Tools. But Should You Avoid Them Altogether?What if you could double or even triple the market's return? Is it worth the risk?
Feb 22, 2026 by Cory RenauerArohi Asset Exits a Big Software Bet by Selling 1.7M DoubleVerify (DV) Shares Worth $20.6 MillionDoubleVerify provides digital media measurement and analytics tools for advertisers and publishers across multiple sectors.
Feb 22, 2026 by Dominic BasultoCould Buying XRP Today Set You Up for Life?Turning a modest upfront investment in XRP into life-changing wealth is harder than it sounds.
Feb 22, 2026 by Jonathan PoncianoNurix Stock Is Down 6% This Past Year, but One Biotech Fund Still Boosted Its Bet By $63 MillionNurix Therapeutics develops targeted cancer and immune disorder therapies, supported by partnerships with leading pharma companies.
Feb 22, 2026 by Jonathan PoncianoBiotech-Focused Fund Adds $12 Million to Immunome Bet as Stock Surges 120%This clinical-stage biotech develops antibody therapies for cancer and infectious diseases, leveraging proprietary discovery platforms.
Feb 22, 2026 by Justin PopeJohnson & Johnson: This Dividend King Could Anchor a Millionaire Retirement PortfolioIt's about striking that perfect balance between chasing growth and protecting what you already have.
Feb 22, 2026 by Jonathan PoncianoInvestor Slashes $70 Million From Zymeworks as Stock Jumps 60% in a YearThis clinical-stage biotech develops targeted cancer therapies, leveraging bispecific antibodies and strategic industry partnerships.
Feb 22, 2026 by Courtney CarlsenVertiv Stock: Buy, Sell, or Hold?Vertiv has seen incredibly strong demand from data center operators for its cooling and power solutions.
Feb 22, 2026 by Jonathan PoncianoBiotech Investor Adds $3 Million to Krystal Biotech as Revenue Hits $389 Million in 2025Krystal Biotech develops redosable gene therapies targeting rare skin diseases, with a late-stage clinical pipeline and expanding portfolio.
Feb 22, 2026 by Jonathan PoncianoBiotech Fund Doubles Down With $49 Million Scholar Rock Buy as Shares Climb 26%Scholar Rock develops therapies for neuromuscular and oncological diseases, leveraging a proprietary platform to target unmet medical needs.
